Takeda Pharmaceutical said on November 24 that its multiple myeloma treatment (MM) Ninlaro (ixazomib) received conditional marketing authorization from the European Commission for use in combination with lenalidomide and dexamethasone in previously treated MM patients. The EU nod comes after…
To read the full story
Related Article
- In a Turnaround, EU Panel Backs Takeda’s Ninlaro for Conditional Approval
September 21, 2016
- Takeda’s Myeloma Drug Hopeful Ninlaro Rebuffed by CHMP
May 31, 2016
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





